Universe's 15min chart shows KDJ Death Cross, bearish Marubozu pattern detected.
PorAinvest
lunes, 13 de octubre de 2025, 12:37 pm ET1 min de lectura
GLTO--
Galecto Inc., focused on developing small-molecule drugs targeting fibrosis and cancer, saw the largest increase in momentum this week, rising from a score of 9.3 on Oct. 1 to 96.64. The stock is trading far above its 50-day moving average of $3.77 at $15.70 [1].
Xenetic Biosciences Inc., which develops cancer treatments that help the immune system fight tumors, saw a momentum gain of 75.56 points, rising from 21.97 to 97.53. The stock is also trading above its 50-day moving average of $3.23 at $9.70 [1].
Universe Pharmaceuticals Inc. went from a score of 12.95 to 82.24, trading above its 50-day moving average of $4.02 at $6.40, and is up more than 50% over the past month [1].
Alaunos Therapeutics, Inc., which develops cell therapies that use a patient's own immune cells to fight cancer, gained 68.77 points since last week, rising from 15.88 to 84.65. The stock is trading above its 50-day moving average of $2.43 at $3.95 and has gained more than 60% over the past month [1].
However, Universe Pharmaceuticals Inc. faces bearish signals according to the 15-minute chart. A KDJ Death Cross and a Bearish Marubozu at 10/13/2025 12:30 indicate a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and it is likely that bearish momentum will continue .
TCRT--
UPC--
XBIO--
According to the 15-minute chart, Universe has triggered a KDJ Death Cross and a Bearish Marubozu at 10/13/2025 12:30. This indicates a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and it is likely that bearish momentum will continue.
Healthcare and biotech stocks have been lagging behind broader markets this year, but a growing number of names have shown significant momentum. According to Benzinga's Edge Stock Rankings system, four biotech stocks have posted sharp increases in bullish momentum over the past week. These stocks are Galecto Inc. (NASDAQ:GLTO), Xenetic Biosciences Inc. (NASDAQ:XBIO), Universe Pharmaceuticals Inc. (NASDAQ:UPC), and Alaunos Therapeutics, Inc. (NASDAQ:TCRT).Galecto Inc., focused on developing small-molecule drugs targeting fibrosis and cancer, saw the largest increase in momentum this week, rising from a score of 9.3 on Oct. 1 to 96.64. The stock is trading far above its 50-day moving average of $3.77 at $15.70 [1].
Xenetic Biosciences Inc., which develops cancer treatments that help the immune system fight tumors, saw a momentum gain of 75.56 points, rising from 21.97 to 97.53. The stock is also trading above its 50-day moving average of $3.23 at $9.70 [1].
Universe Pharmaceuticals Inc. went from a score of 12.95 to 82.24, trading above its 50-day moving average of $4.02 at $6.40, and is up more than 50% over the past month [1].
Alaunos Therapeutics, Inc., which develops cell therapies that use a patient's own immune cells to fight cancer, gained 68.77 points since last week, rising from 15.88 to 84.65. The stock is trading above its 50-day moving average of $2.43 at $3.95 and has gained more than 60% over the past month [1].
However, Universe Pharmaceuticals Inc. faces bearish signals according to the 15-minute chart. A KDJ Death Cross and a Bearish Marubozu at 10/13/2025 12:30 indicate a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and it is likely that bearish momentum will continue .
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios